1stOncology™: Cancer Intelligence Service – Page 12374 – 1stOncology is recognized as a Top 10 Global Pharma Analytic Provider

Syndax Announces Participation at Two Upcoming Investor Conferences

On February 18, 2020 Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, reported that members of its management team will participate in two upcoming investor conferences (Press release, Syndax, FEB 18, 2020, View Source [SID1234554438]). The details for the two conferences are:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

Schedule Your 30 min Free Demo!

BTIG Targeted Therapeutics Conference at the St. Regis New York on Monday, February 24, 2020. Panel discussion at 1:00 p.m. ET.
Cowen 40th Annual Healthcare Conference at the Boston Marriott Copley Place on Wednesday, March 4, 2020. Presentation at 11:20 a.m. ET.
A live webcast of the Cowen presentation can be accessed from the Investor section of the Company’s website at www.syndax.com, where a replay of the event will also be available for a limited time.

Selecta Biosciences to Present at the 9th Annual SVB Leerink Global Healthcare Conference

On February 18, 2020 Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR, reported that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will participate in a fireside chat at the 9th Annual SVB Leerink Global Healthcare Conference in New York on Tuesday, February 25 at 11:00 a.m. Eastern Time (Press release, Selecta Biosciences, FEB 18, 2020, View Source [SID1234554437]). A live webcast and a copy of the presentation will be available on the Investors & Media section of the Selecta website at www.selectabio.com.

RedHill Biopharma to Present at the 9th Annual SVB Leerink Global Healthcare Conference

On February 18, 2020 RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on the commercialization and development of proprietary drugs for the treatment of gastrointestinal diseases, reported that Mr. Dror Ben-Asher, RedHill’s Chief Executive Officer, will present a corporate overview at the 9th Annual SVB Leerink Global Healthcare Conference on Wednesday, February 26, 2020, at 10:00 a.m. EST, at the Lotte New York Palace, New York (Press release, RedHill Biopharma, FEB 18, 2020, View Source [SID1234554436]).

The presentation will be broadcast live and available via replay for 30 days on the Company’s website, View Source Please access the website at least 15 minutes ahead of the conference call to register.

Perrigo Increases its Dividend by 7%

On February 18, 2020 Perrigo Company plc (NYSE; TASE: PRGO), a leading global provider of "Quality, Affordable Self-Care Products", reported that its Board of Directors, consistent with its transformation into a consumer self-care company, approved a 7% increase to the company’s quarterly dividend to $0.225 per share from $0.21 per share (Press release, Perrigo Company, FEB 18, 2020, View Source [SID1234554435]). This dividend increase marks the 17th consecutive year Perrigo has increased its dividend.

The cash dividend is payable on March 17, 2020 to shareholders of record on February 28, 2020.

Onconova Therapeutics Announces Participation in Two Upcoming International Conferences

On February 18, 2020 Onconova Therapeutics, Inc. (NASDAQ: ONTX), a Phase 3-stage biopharmaceutical company discovering and developing novel products to treat cancer, with an initial focus on myelodysplastic syndromes (MDS), reported that the Company will be participating in two upcoming international conferences (Press release, Onconova, FEB 18, 2020, View Source [SID1234554434]):

1. RAS-Targeted Drug Discovery Summit/Europe
February 25-27
Vienna, Austria

Presentation Details:

Title: Rigosertib is a Unique Small Molecule RAS Antagonist: Scientific & Clinical Studies
Date/Time: Thursday, February 27th, 9:00 AM Central European Time
Venue: Hilton Vienna Plaza
Presenter: Steven M. Fruchtman, M.D., President & CEO of Onconova

About RAS and Rigosertib:

There is a high frequency of RAS mutations in cancer that leads to the belief that mutations of the RAS Pathway provide a proliferative advantage and thus are involved in the pathogenesis of cancer. As a result, targeting the RAS pathway has been the objective of scientific research for decades. As published in the journal Cell in 2016, and now under investigation in a pivotal Phase 3 Trial, rigosertib targets the mutated RAS pathway by its interaction with RAS effector proteins containing the RAS Binding Domain. The RAS-Targeted Drug Discovery Summit provides an opportunity to showcase the potential for rigosertib in MDS and in other RAS-driven cancers, such as KRAS-mutated lung cancer and colorectal cancer, and RAS-driven pediatric cancers as well. Onconova will review its INSPIRE Trial for which the Company anticipates reporting top-line data for second-line, higher-risk MDS patients in the first half of this year, following full enrollment and 288 death events. Dr. Fruchtman looks forward to joining colleagues at the Summit to discuss advancements in rigosertib’s development as well as the progress the Company and others have made in targeting RAS.

2. 2nd Regional Symposium on MDS
March 5-6
Tel Aviv, Israel

"We are pleased to participate in the MDS Conference in Tel Aviv where experts from around the globe will be presenting new data on the diagnosis and management of MDS," said Dr. Steven Fruchtman.